Abstract:Background Globally, breast cancer, with diverse subtypes and prognoses, necessitates tailored therapies for enhanced survival rates. A key focus is glutamine metabolism, governed by select genes. This study explored genes associated with T cells and linked them to glutamine metabolism to construct a prognostic staging index for breast cancer patients for more precise medical treatment. Methods Two frameworks, T‐cell related genes (TRG) and glutamine metabolism (GM), stratified breast cancer patients. TRG analysis identified key genes via hdWGCNA and machine learning. T‐cell communication and spatial transcriptomics emphasized TRG's clinical value. GM was defined using Cox analyses and the Lasso algorithm. Scores categorized patients as TRG_high+GM_high (HH), TRG_high+GM_low (HL), TRG_low+GM_high (LH), or TRG_low+GM_low (LL). Similarities between HL and LH birthed a "Mixed" class and the TRG_GM classifier. This classifier illuminated gene variations, immune profiles, mutations, and drug responses. Results Utilizing a composite of two distinct criteria, we devised a typification index termed TRG_GM classifier, which exhibited robust prognostic potential for breast cancer patients. Our analysis elucidated distinct immunological attributes across the classifiers. Moreover, by scrutinizing the genetic variations across groups, we illuminated their unique genetic profiles. Insights into drug sensitivity further underscored avenues for tailored therapeutic interventions. Conclusion Utilizing TRG and GM, a robust TRG_GM classifier was developed, integrating clinical indicators to create an accurate predictive diagnostic map. Analysis of enrichment disparities, immune responses, and mutation patterns across different subtypes yields crucial subtype‐specific characteristics essential for prognostic assessment, clinical decision‐making, and personalized therapies. Further exploration is warranted into multiple fusions between metrics to uncover prognostic presentations across various dimensions.

Multi-stage Clustering of Breast Cancer for Precision Medicine

Multi-parameter systematic strategies for predictive, preventive and personalised medicine in cancer

Leveraging a Joint of Phenotypic and Genetic Features on Cancer Patient Subgrouping

Structural deep clustering network for stratification of breast cancer patients through integration of somatic mutation profiles

Patient-Specific Network for Personalized Breast Cancer Therapy with Multi-Omics Data

Precision Medicine for Breast Cancer: The Paths to Truly Individualized Diagnosis and Treatment

A Robust Personalized Classification Method for Breast Cancer Metastasis Prediction

A Clustering-Based Approach to Predict Outcome in Cancer Patients

Toward Precision Breast Cancer Survival Prediction Utilizing Combined Whole Genome-Wide Expression and Somatic Mutation Analysis

An ensemble algorithm integrating consensus-clustering with feature weighting based ranking and probabilistic fuzzy logic-multilayer perceptron classifier for diagnosis and staging of breast cancer using heterogeneous datasets

[Multi-Gene Assay Profiling Testing and Individualized Therapy in Breast Cancer].

Machine learning-informed liquid-liquid phase separation for personalized breast cancer treatment assessment

MLPA: A Multi-scale Digital Twin Framework for Personalized Cancer Simulation and Treatment Optimization

Bayesian network-driven clustering analysis with feature selection for high-dimensional multi-modal molecular data

[Breast cancer research in the era of precision medicine].

A Clustering Approach in Developing Prognostic Systems of Cancer Patients

Identification of Gene Expression in Different Stages of Breast Cancer with Machine Learning

Integrated Multiomic Profiling of Breast Cancer in the Chinese Population Reveals Patient Stratification and Therapeutic Vulnerabilities

Identification of Breast Cancer Subtypes by Integrating Genomic Analysis with the Immune Microenvironment

Precision unveiled: Synergistic genomic landscapes in breast cancer—Integrating single‐cell analysis and decoding drug toxicity for elite prognostication and tailored therapeutics

Precision Medicine in Breast Cancer Research